170372 ⎘
Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates; Assays involving proteins of known structure or function as defined in the subgroups; Details Amyloid plaque core protein
Methods and Dosing Regimens for Preventing or Delaying Onset of Alzheimer's Disease and Other Forms of Dementia and Mild Cognitive Impairment
#2METHODS FOR REMOTE BLOOD COLLECTION, EXTRACTION AND ANALYSIS OF NEURO BIOMARKERS
#3METHODS OF GENERATING BRAIN ORGANOIDS AND REPAIRING NON-VIABLE EMBRYOID BODIES
#4M13 bacteriophages displaying peptide motifs targeting amyloid-beta, methods and uses thereof
#5METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS
#6PROTEIN AGGREGATION ASSAY AND METHODS OF USING THE SAME
#7METHODS OF DIAGNOSING AND TREATING NEURODEGENERATIVE DISORDERS
#8SURFACE-FUNCTIONALIZED OPTICAL ELEMENT
#9METHOD AND DEVICE FOR IDENTIFYING STRUCTURAL POLYMORPHISM OF FIBROUS PROTEIN OR PEPTIDE
#10DIAGNOSTIC INDICES FOR NEURODEGENERATIVE CONDITIONS
#11METHOD AND SYSTEM FOR BRAIN LIQUID BIOPSY AND BRAIN TREATMENT METHOD
#12METHODS TO DETECT AB PROTEOFORMS AND USE THEREOF
#13DEVICE AND METHOD FOR THE DETECTION OF BIOMARKERS ASSOCIATED WITH NEURODEGENERATIVE DISEASES
#14METHODS AND COMPOSITIONS FOR TAUOPATHY DIAGNOSIS AND TREATMENT
#15METHOD FOR SCREENING DRUGS FOR TREATING MULTIPLE-VARIANT CORONAVIRUS DISEASE
#16Antibodies to Amyloid Beta
#17PEPTIDE TO TREAT ALPHA-SYNUCLEIN AMYLOID BASED DISORDERS
#18PHOSPHO-TAU ANTIBODIES AND METHODS OF USE
#19METHOD FOR DETECTING SOLUBLE OLIGOMERIC AMYLOID BETA
#20MEANS AND METHODS FOR HIGH-THROUGHPUT GLYCOPROFILING OF PROTEINS
#21MONOCLONAL ANTIBODY COMPOSITION FOR QUANTITATIVE DETECTION OF AMYLOID IN HUMAN BODY FLUID AND USES
#22METHOD FOR EVALUATING ACTIVITY OF INHIBITING OR PROMOTING AGGREGATION OF AGGREGATING PROTEINS
#23BIOLOGICAL DEVICES FOR THE DETECTION OF ALZHEIMER'S DISEASE AND CONCUSSIONS AND METHODS OF USE THEREOF
#24METHODS OF DETERMINING A TREATMENT PROTOCOL FOR AND/OR A PROGNOSIS OF A PATIENT’S RECOVERY FROM A BRAIN INJURY
#25COMBINATION OF BIOMARKERS, AND METHOD FOR DETECTING COGNITIVE DYSFUNCTION OR RISK THEREOF BY USING SAID COMBINATION
#26BIOMARKERS FOR ALZHEIMER'S DISEASE TREATMENT
#27AMYLOID BETA DETECTION BY MASS SPECTROMETRY
#28Supermere Nanoparticles and Methods of Isolation and Use Thereof
#29A Beta Biomarker of Alzheimer’s Disease Model Mouse and Analysis Method Thereof
#30A METHOD FOR REPRODUCIBLE APTAMER SELECTION USED TO IDENTIFY APTAMERS THAT BIND TO UNKNOWN BIOMARKERS
#31PHAGE MEDIATED IMMUNO-PCR FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE
#32METHODS OF USE OF ANTI-TREM2 ANTIBODIES
#33DIGESTED DDIT4L PRODUCT AS DIAGNOSTIC MARKER FOR ALZHEIMER'S DISEASE
#34ALPHA-SYNUCLEIN DETECTION ASSAY
#35METHODS FOR DIAGNOSING AND/OR TREATING ALZHEIMER'S DISEASE
#36ANTIBODIES TO AMYLOID BETA
#37NOVEL POTENCY ASSAY FOR ANTIBODY-BASED DRUGS AND USEFUL MEANS THEREFOR
#38ALPHA-SYNUCLEIN DETECTION ASSAY AND METHOD FOR DIAGNOSING ALPHA-SYNUCLEINOPATHIES
#39IN VITRO POINT-OF-CARE ASSAY METHOD/PROCESS USING COMBINATION OF BIOACTIVATED NON-MAGNETIC AND MAGNETIC QUANTUM DOTS FOR RAPID IMMUNO-OPTOMAGNETIC DETECTION OF SERUM BIOMARKERS IN FREE SOLUTION
#40APP iRNA Compositions and Methods of Use Thereof for Treating or Preventing Diseases Characterized by Enlarged Endosomes
#41SELECTION AND TREATMENT OF SUBJECTS HAVING A CIRCULATING MYELOID CELL INFLAMMATORY PHENOTYPE
#42METHODS FOR TREATING ALZHEIMER'S DISEASE
#43METHODS AND DEVICES FOR DETECTING CEREBROSPINAL FLUID LEAKAGE
#44RED BLOOD CELL-DERIVED MAGNETIC IMMUNO-PARTICLE AND USE THEREOF
#45PHOSPHO-TAU ANTIBODIES AND METHODS OF USE
#46Phospho-TAU antibodies and methods of use
#47A NOVEL ANTIBODY FOR DETECTION OF AMYLOID BETA 42 (AB42)
#48Hyperspectral Image-Guided Ocular Imager for Alzheimer's Disease Pathologies
#49METHOD FOR MEASURING EXTRACELLULAR VESICLES, METHOD FOR ACQUIRING INFORMATION ON NEURODEGENERATION, METHOD FOR ISOLATING EXTRACELLULAR VESICLES, AND REAGENT KIT
#50INHIBITORS OF AMYLOID BETA OLIGOMERIZATION AND THERAPEUTIC USES THEREOF
#51METHOD FOR DETECTING AMYLOID-ß BOUND TO BRAIN-NEURONALCELL-DERIVED EXOSOME IN BLOOD, KIT FOR DETECTION OF AMYLOID-ß BOUND TO BRAIN-NEURONAL-CELL-DERIVED EXOSOME IN BLOOD, AND METHOD FOR EVALUATING ACCUMULATION LEVEL OF AMYLOID-ß IN BRAIN
#52METHODS AND SYSTEMS FOR DIAGNOSING DISEASES
#53Biomarker and Druggable Target of Neurodegeneration
#54METHODS OF DETERMINING A TREATMENT PROTOCOL FOR AND/OR A PROGNOSIS OF A PATIENT’S RECOVERY FROM A BRAIN INJURY RESULTING FROM A HYPOXIC EVENT
#55Digital Protein Misfolding Assays
#56METHODS OF DIAGNOSING AND PREDICTING RENAL DECLINE
#57METHOD FOR CREATING CALIBRATION CURVE AND METHOD FOR MEASURING AMYLOID ß-RELATED PEPTIDE
#58CLEARANCE ASSAY
#59Biofluid-Based Methods for Diagnosing Alzheimer’s Disease-Associated Conditions
#60METHODS AND SYSTEMS FOR DIAGNOSING DISEASES
#61QUALITY CONTROL STANDARD SOLUTION USED IN PEPTIDE ASSAY, AND QUALITY CONTROL OF PEPTIDE ASSAY
#62AMYLOID PROTEIN MODIFYING SORTASES AND USES THEREOF
#63METHOD FOR THE DETECTION AND TREATMENT OF PROTEINOPATHIES
#64ANTI-PT217 TAU ANTIBODY
#65IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID beta (Abeta) AMINO ACID SEQUENCES AND USES THEREOF
#66ANTI-TAU ANTIBODIES AND METHODS OF USE
#67METHOD BY WHICH BIOSENSOR DEVICE DETECTS ANTIGEN BY USING MULTIPLE FREQUENCIES
#68ANALYSIS METHOD
#69DETECTION OF DEBRIS IN RECIRCULATING PHAGOCYTES
#70BIOMARKER COMPOSITION FOR DIAGNOSING DEGENERATIVE BRAIN DISEASES
#71METHOD FOR DIAGNOSING AMYLOID DISEASES
#72Integrated microfluidic system for automated multiplex analyte detection
#73RF biosensor and manufacturing method thereof
#74DETERMINATION AGENT AND DETERMINATION METHOD FOR TAUOPATHY AND DEMENTIA-RELATED DISEASES
#75TDP-43 BIOSENSOR CELL LINES
#76CSF PHOSPHORYLATED TAU AND AMYLOID BETA PROFILES AS BIOMARKERS OF TAUOPATHIES
#77METHODS FOR QUANTIFICATION OF AMYLOID BETA PEPTIDES IN PLASMA BY MASS SPECTROMETRY
#78ANTIBODIES RECOGNIZING TAU
#79METHOD OF IDENTIFYING BIOMARKERS OF NEUROLOGICAL DISEASES AND DIAGNOSIS OF NEUROLOGICAL DISEASES
#80TAU EPITOPE AND BINDING MOLECULES
#81METHOD FOR IMMUNOASSAY OF AMYLOID BETA IN BLOOD, AND KIT FOR SAME
#82PROBES FOR IMAGING B-AMYLOID AND INHIBITION OF B-AMYLOID AGGREGATION
#83IMMUNOTHERAPEUTIC MODULATION OF AMYLOIDOGENIC DISEASE USING NON-FIBRILLOGENIC, NON-AMYLOIDOGENIC POLYMERIZED PROTEINS AND PEPTIDES
#84TWO-PHOTON FLUORESCENT PROBE COMPOUND SELECTIVE FOR AMYLOID BETA PLAQUES AND METHOD FOR IMAGING AMYLOID BETA PLAQUES USING SAME
#85METHOD FOR COLLECTING EXTRACELLULAR VESICLES DERIVED FROM NERVOUS SYSTEM CELLS
#86METHOD OF DETECTING A NEURODEGENERATIVE DISEASE
#87GAMMA-SECRETASE STABILIZING COMPOUND SCREENING ASSAY
#88Biomarkers and Methods for Measuring and Monitoring Inflammatory Disease Activity
#89SENSOR CHIP AND METHODS THEREOF
#90TEST STRIP AND METHOD FOR DETECTING AMYLOID BETA IN URINE
#91AMYLOID BETA OLIGOMER DETECTION METHOD, AMYLOID BETA OLIGOMER DETECTION DEVICE, AND AMYLOID BETA OLIGOMER DETECTION PROGRAM
#92Amyloid beta detection by mass spectrometry
#93METHODS TO DETECT MTBR TAU ISOFORMS AND USE THEREOF
#94MONOCLONAL ANTIBODY AGAINST AMYLOID BETA, AND METHOD FOR MEASURING AMYLOID BETA-RELATED PEPTIDE USING SAID ANTIBODY
#95TARGETS AND METHODS OF DIAGNOSING, MONITORING AND TREATING FRONTOTEMPORAL DEMENTIA
#96METHODS OF DETERMINING A TREATMENT PROTOCOL FOR AND/OR A PROGNOSIS OF A PATIENT'S RECOVERY FROM A BRAIN INJURY
#97ANTIBODY ARRAY FOR MEASURING A PANEL OF AMYLOIDS
#98METHODS OF DETERMINING A TREATMENT PROTOCOL FOR AND/OR A PROGNOSIS OF A PATIENT'S RECOVERY FROM A BRAIN INJURY
#99METHODS AND MEANS FOR STRATIFICATION OF AN INDIVIDUAL SUFFERING FROM, OR SUSPECTED TO SUFFER FROM, A PROGRESSIVE NEURODEGENERATIVE DISEASE
#100Method for diagnosis of Alzheimer's disease using microrna
#101METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE USING SILVER NANOGAP SHELL
#102COMPOUNDS AND METHODS TARGETING HUMAN TAU
#103DETECTION OF MISFOLDED TAU PROTEIN
#104MULTIPLEXED ASSAY AND METHODS OF USE THEREOF
#105BIOMARKERS FOR DETERMINING SURVIVAL AND THERAPEUTIC RESPONSE IN CERVICAL CANCER
#106METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES
#107OLIGOMER-SELECTIVE FLUORESCENT INDICATOR DYES
#108METHODS AND COMPOSTIONS OF DETECTING AND TREATING NEURODEGENERATIVE DISORDERS
#109NEW ANTI TAU SVQIVYKPV EPITOPE SINGLE DOMAIN ANTIBODY
#110Alpha-synuclein detection assay and method for diagnosing alpha- synucleinopathies
#111METHOD FOR DETECTING SOLUBLE OLIGOMERIC AMYLOID BETA
#112Anti-Tau antibodies and methods of use
#113USE OF Aß34 TO ASSESS ALZHEIMER’S DISEASE PROGRESSION
#114METHODS FOR DIAGNOSING A CEREBRAL AMYLOID ANGIOPATHY
#115METHOD FOR DIAGNOSING DEMENTIA OR DETERMINING THE RISK OF DEVELOPING DEMENTIA
#116Alpha-synuclein detection assay and method for diagnosing alpha-synucleinopathies
#117METHODS AND DOSING REGIMENS FOR PREVENTING OR DELAYING ONSET OF ALZHEIMER'S DISEASE AND OTHER FORMS OF DEMENTIA AND MILD CONGNITIVE IMPAIRMENT
#118Blood-based methods for determining Aβ amyloidosis
#119RGO-BASED BIOSENSOR, MANUFACTURING METHOD OF SAME, AND DETECTION METHOD FOR BIOMATERIAL
#120AMYLOSPHEROID (ASPD)-LIKE STRUCTURE AND PHARMACEUTICAL COMPOSITION
#121Antibodies specific for hyperphosphorylated tau and methods of use thereof
#122Human induced pluripotent stem cell lines for modeling Alzheimer's disease and usage thereof
#123PEPTIDE ANALYZING METHOD
#124ANTIBODY THAT SPECIFICALLY RECOGNIZES N TERMINUS OF APP669-x, AND IMMUNOASSAY METHOD
#125N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
#126Methods of binding amyloid beta protein having pyroglutamate at the third amino acid residue (3pE abeta) in vivo using anti-3pE abeta antibodies or antigen-binding fragments thereof
#127Antibodies recognizing tau
#128DETECTION OF MISFOLDED PROTEINS
#129Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide
#130Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide
#131Compositions comprising cyclic peptides derived from an A-beta peptide
#132METHODS OF DETECTING NEURODEGENERATIVE DISEASE
#133METHODS AND REAGENTS FOR IMPROVED DETECTION OF AMYLOID BETA PEPTIDES
#134COMPOSITION FOR SCREENING ONGOING PROGRESS OF ALZHEIMER'S DISEASE BY USING BETA AMYLOID OLIGOMER IN NASAL DISCHARGE SPECIMEN AND METHOD FOR SCREENING ONGOING PROGRESS OF ALZHEIMER'S DISEASE BY USING SAME
#135Biological devices and methods of use thereof for the detection of amyloid proteins
#136AMYLOID-BINDING COMPOUNDS AND METHODS OF USE THEREOF
#137METHODS FOR DEVELOPING PHARMACEUTICALS FOR TREATING NEURODEGENERATIVE CONDITIONS
#138Biomarkers and Methods for Measuring and Monitoring Inflammatory Disease Activity
#139Method for diagnosis of Alzheimer's disease using microRNA
#140Blood cell biomarker for late onset Alzheimer's disease
#141Hyperspectral image-guided ocular imager for alzheimer's disease pathologies
#142METHOD FOR QUANTIFYING PROTEIN AGGREGATES OF A PROTEIN MISFOLDING DISEASE IN A SAMPLE
#143Amyloid-beta-binding peptides and the use thereof for the treatment and diagnosis of Alzheimer's disease
#144ANTIBODY ARRAY FOR MEASURING A PANEL OF AMYLOIDS
#145METHOD OF DISTINGUISHING BETWEEN DIFFERENT NEURODEGENERATIVE DISEASES
#146METHOD FOR ACQUIRING INFORMATION ON ANALYTE
#147Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD
#148Antibodies and Vaccines for Use in Therapeutic and Diagnostic Methods for Alpha-Synuclein-Related Disorders
#149Antibodies specific for hyperphosphorylated tau and methods of use thereof
#150Humanized antibodies binding to amyloid-beta (A-beta)
#151Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers
#152BRAIN SPECIFIC EXOSOME BASED DIAGNOSTICS AND EXTRACORPOREAL THERAPIES
#153Methods of detecting pyroglutamate amyloid beta protein (3pE Aβ) using anti-3pE Aβ antibodies
#154FKBP52-TAU INTERACTION AS A NOVEL THERAPEUTICAL TARGET FOR TREATING THE NEUROLOGICAL DISORDERS INVOLVING TAU DYSFUNCTION
#155Humanized antibodies
#156Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
#157AFFINITY CAPTURE OF CIRCULATING BIOMARKERS
#158HUMANIZED ANTIBODY
#159System and method for multi-parameter spectroscopy
#160Structure-based peptide inhibitors that target the Tau VQIINK fibrillization segment
#161Conformational mimotopes for detecting specific antibodies
#162Anti-tau antibodies and methods of use
#163Methods for ameliorating memory impairment in a memory disorder caused by neuronal cell death or Abeta aggregation using a peptide
#164Detection of Brain Injury or Neurological Disease using Tau Protein
#165BIOMARKERS OF BLOOD-BRAIN BARRIER DYSFUNCTION
#166Γ-secretase stabilizing compound screening assay
#167Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
#168Antibodies recognizing tau
#169Method for identifying inhibitors of primary nucleation of amyloid-beta aggregation
#170PEPTIDE OR COLLECTION OF PEPTIDES DERIVED FROM AMYLOID PRECURSOR PROTEIN
#171Alpha-synuclein detection assay and method for diagnosing alpha-synucleinopathies
#172COMBINED ASSAY FOR THE DIFFERENTIAL DIAGNOSIS OF THE ALZHEIMER'S DISEASE
#173Method for the preselection of drugs for protein misfolding diseases
#174METHOD OF DISTINGUISHING BETWEEN DIFFERENT NEURODEGENERATIVE DISEASES
#175ANTIBODY BASED REAGENT THAT SPECIFICALLY RECOGNIZES TOXIC OLIGOMERIC FORM OF BETA-AMYLOID
#176Antibodies specific for hyperphosphorylated tau and methods of use thereof
#177Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
#178METHODS FOR ESTIMATING MISFOLDED PROTEIN CONCENTRATION IN FLUIDS AND TISSUE BY QUANTITATIVE PMCA
#179Compositions and methods for AL amyloid detection and uses thereof
#180System and method for multi-parameter spectroscopy
#181Method for detecting aggregate of aggregate-forming polypeptide
#182Anti-Tau Antibodies and methods of use
#183Anti-Tau antibodies and methods of use
#184DETECTION OF NEURODEGENERATIVE DISEASES
#185Methods for measuring concentrations of biomolecules in biofluids
#186D-enantiomeric peptides derived from D3 and use thereof
#187Targeting immunotherapy for amyloidosis
#188Compound for specifically binding to amyloid β-protein
#189Amyloid β oligomer detection method, amyloid β oligomer detection device, and amyloid β oligomer detection program
#190Identifying amyloidogenic proteins and amyloidogenic risk
#191Method for treating blood, blood products and organs
#192HUMANIZED ANTIBODY IGG1
#193Optical method for the detection of Alzheimer's disease using curcumin
#194Apparatus and method for cerebral microdialysis to treat neurological disease, including Alzheimer's, Parkinson's or multiple sclerosis
#195SOLUBLE HIGH MOLECULAR WEIGHT (HMW) TAU SPECIES AND APPLICATIONS THEREOF
#196Method for detecting test substance and reagent kit for detecting test substance
#197Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereof
#198Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
#199Detection of misfolded tau protein
#200HUMANIZED ANTIBODY
#201N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
#202EPITOPES IN AMYLOID BETA AND CONFORMATIONALLY-SELECTIVE ANTIBODIES THERETO
#203Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
#204NON-SURGICAL METHOD OF TREATMENT FOR CATARACT
#205Antibody-based molecules selective for the Ser404 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
#206System and method for multi-parameter spectroscopy
#207Method for obtaining information of test substance
#208Antibody array for measuring a panel of amyloids
#209Method of detecting an APP Alzheimer's disease marker peptide in patients with Alzheimer's disease
#210Synthetic blood vessels and uses thereof
#211Method for purifying pure thioflavin T, method for producing pure thioflavin T, composition including thioflavin T, and amyloid detection method
#212Liquid-liquid extraction methods for purifying and producing pure thioflavin T by monitoring light emission intensity of thioflavin T
#213METHOD OF IDENTIFYING BIOMARKERS OF NEUROLOGICAL DISEASES AND DIAGNOSIS OF NEUROLOGICAL DISEASES
#214SYSTEM AND METHODS FOR THE DETECTION OF BIOMARKERS OF NEURODEGENERATIVE DISORDERS
#215Methods for providing information relevant to diagnosis of neurodegenerative disorder
#216Multiplex biomarker for use in evaluation of state of accumulation of amyloid B in brain, and analysis method for said evaluation
#217NEURODEGENERATIVE DISORDERS
#218AFFINITY CAPTURE OF CIRCULATING BIOMARKERS
#219Method for treatment of traumatic brain injury targeting aggregated peptides
#220MODULAR CHEMIRESISTIVE SENSOR
#221DETECTION OF MISFOLDED PROTEINS
#222Detection of Misfolded Amyloid Beta Protein
#223DIAGNOSTIC TEST FOR ALZHEIMER'S DISEASE BASED ON IDENTIFICATION OF A PROTEOLYTIC PATHWAY
#224FKBP52-TAU INTERACTION AS A NOVEL THERAPEUTICAL TARGET FOR TREATING THE NEUROLOGICAL DISORDERS INVOLVING TAU DYSFUNCTION
#225Antibody Therapy for Amyloid Beta Disease
#226Nano-biomimetic MEMS-transformer devices of making and an application in energy-sensory images thereto
#227Antibodies to pyroglutamate amyloid-β and uses thereof
#228Humanized antibodies
#229Methods of treating Alzheimer's disease
#230Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
#231Cyclic, amyloid beta-binding peptides and the use thereof
#232Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
#233Making of organic nanobiomimetic memristor and memcapacitors and its applications in dual sensing of a biomarker in neurodegenerative diseases thereto
#234Method for diagnosing diseases through oligomer analysis of abnormally aggregated proteins
#235Specific amyloid beta binding peptides and the use of same for treating and diagnosing alzheimer's dementia
#236Monoclonal antibodies against amyloid beta protein and uses thereof
#237A PEPTIDE OR COLLECTION OF PEPTIDES DERIVED FROM AMYLOID PRECURSOR PROTEIN
#238ANTIBODY HIGHLY SPECIFICALLY RECOGNIZING TURN STRUCTURE AT 22- AND 23-POSITIONS IN AMYLOID BETA
#239METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES
#240COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF DISORDERS ASSOCIATED WITH PROTEIN OR PEPTIDE OLIGOMERS
#241System and method for early detection of Alzheimers by detecting amyloid-beta using orbital angular momentum
#242Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
#243ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO-ALZHEIMER'S DISEASE-SPECIFIC MOLECULAR BIOMARKERS (ADSMB)
#244Method for producing a standard for detecting protein aggregates of a protein misfolding disease, standard and use thereof
#245Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
#246METHOD FOR DETECTING MOLECULES THAT INHIBIT THE INTERACTION OF CD36 PROTEIN WITH AMYLOID BETA
#247Novel Method for the Detection of pGlu-Abeta Peptides
#248Chiral Substituted Amyloid Beta Peptides
#249METHODS AND COMPOSITIONS FOR TREATING AMYLOID DEPOSITS
#250D-enantiomeric peptides derived from D3 and use thereof
#251Detection of aggregated proteins associated with neurodegenerative disease using a photooxidation-induced amplification immunoassay
#252Alzheimer's Disease
#253Method of providing disease-specific binding molecules and targets
#254Targeting immunotherapy for amyloidosis
#255USE OF FUSION PROTEINS TO IMPROVE THE AVAILABILITY OF ANTIGENIC PEPTIDE EPITOPES IN IMMUNOASSAYS
#256METHOD FOR DETECTING AGGREGATE FORM OF AGGREGATE-FORMING POLYPEPTIDE
#257Monoclonal antibody against human tau protein
#258Biomarkers in nasal exhaled breath
#259IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT
#260Antibody array for measuring a panel of amyloids
#261AGENTS USEFUL IN DIAGNOSTIC AND THERAPY OF BETA-AMYLOID AGGREGATION RELATED DISORDERS AND SCREENING METHODS
#262Method for quantitative characterization of substances with regard to their properties of binding to amyloid-β (Aβ) conformers
#263METHOD FOR DETECTING SOLUBLE OLIGOMERIC AMYLOID BETA
#264ANTIBODY BASED REAGENT THAT SPECIFICALLY RECOGNIZES TOXIC OLIGOMERIC FORM OF BETA-AMYLOID
#265N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses
#266Surrogate biomarker for evaluating intracerebral amyloid ß peptide accumulation and method for analysis thereof
#267Methods of treating a tauopathy
#268Method for treating blood, blood products and organs
#269Biomarkers and Methods for Measuring and Monitoring Inflammatory Disease Activity
#270Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
#271Compounds binding to neuropathological aggregates
#272METHODS OF DETERMINING AMYLOID BETA TURNOVER IN BLOOD
#273Small molecular probes, processes and use thereof
#274Amyloid beta detection by mass spectrometry
#275Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standards
#276FKBP52-Tau Interaction as a Novel Therapeutical Target for Treating the Neurological Disorders Involving Tau Dysfunction
#277METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
#278Anti-Aβ globulomer 4D10 antibodies
#279Antibodies specific to pyroglutamated Aβ
#280Non-Surgical Method of Treatment for Cataract
#281Mass spectrometry method for polypeptides
#282Antibodies specific for hyperphosphorylated tau and methods of use thereof
#283BRAIN SPECIFIC EXOSOME BASED DIAGNOSTICS AND EXTRACORPOREAL THERAPIES
#284METHOD FOR SCREENING THERAPEUTIC AND/OR PROPHYLACTIC AGENTS FOR ALZHEIMER'S DISEASE
#285Human islet amyloid polypeptide (HIAPP) specific antibodies and uses thereof
#286Anti-Tau antibodies and methods of use
#287ANTIBODIES THAT BIND TO HUMAN TAU AND ASSAY FOR QUANTIFYING HUMAN TAU USING THE ANTIBODIES
#288Methods of treating a tauopathy
#289Oligopeptide and methods for producing conjugates thereof
#290METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS
#291Method for the quantitative characterization of amyloid and/or aggregating peptides and/or proteins in a sample
#292Camelid single-domain antibody directed against amyloid beta and methods for producing conjugates thereof
#293Tau peptides, anti-tau antibodies, and methods of use thereof
#294Measurement method for amyloid precursor protein cleavage peptides
#295METHOD OF DISTINGUISHING BETWEEN DIFFERENT NEURODEGENERATIVE DISEASES
#296ANTIBODIES SPECIFIC FOR THE PROTOFIBRIL FORM OF BETA-AMYLOID PROTEIN
#297Amyloid-beta-binding peptides and the use thereof for the treatment and diagnosis of alzheimer's disease
#298MODIFICATION OF AMYLOID-BETA LOAD IN NON-BRAIN TISSUE
#299HUMANIZED ANTIBODY
#300Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD